scholarly journals Yagya Therapy for Epileptic Seizures: A Case Study

2018 ◽  
Vol 1 (2) ◽  
pp. 37-42
Author(s):  
Lalima Batham ◽  
Lokesh Choudhary ◽  
Alka Mishra ◽  
Vandana Shrivastava

Epileptic seizure is a neurological condition in which brief to long episodes of vigorous shaking, convulsions, blackouts, fainting, unresponsiveness, jerks, etc. occur in the patients. Current treatment approaches are anti-seizure medicines, which patients are bound to take throughout life. These medications are mostly not able to reverse or eradicate the condition. Vedic literature recommends Yagya as a therapy for mental conditions similar to mania, seizure, etc. Yagya-Therapy provides pulmonary inhalation of medicinal-smoke of multiple herbs (generated through oblation in fire along with chanting of Vedic hymns), which have the potential for seizure treatment. A case study is being reported wherein Yagya-Therapy was prescribed to an epileptic seizure patient. Before the start of Yagya-Therapy, the patient (Male/65 years) had been suffering from epileptic seizures (~8-10 episodes annually) since ~3 years (pre-observation). Subsequently, the patient has been doing Yagya-Therapy since past ~3.5 years, wherein only 2-3 episodes occurred during the first year, that too during sleep only, and after that no seizures have been experienced. All this time, the patient continued to take the allopathic medication that he was taking earlier. Thus, Yagya-Therapy can be an effective treatment option for epileptic seizure patients.

2019 ◽  
Author(s):  
Tolga Akkan ◽  
Murat Dagdeviren ◽  
Koca Arzu Or ◽  
Derun Taner Ertugrul ◽  
Mustafa Altay

2020 ◽  
Vol 4 (18) ◽  
pp. 4278-4281 ◽  
Author(s):  
Zahidee Rodriguez ◽  
Andi L. Shane ◽  
Hans Verkerke ◽  
Christopher Lough ◽  
Matthew G. Zimmerman ◽  
...  

Key Points COVID-19 convalescent plasma (CP) may be a safe and effective treatment option in SARS-CoV-2 infection refractory to remdesivir. Infants may benefit from CP despite developing immune systems and donor variability emphasizes the need for characterization prior to use.


2016 ◽  
pp. AAC.01907-16 ◽  
Author(s):  
Manju Bala ◽  
Vikram Singh ◽  
Aradhana Bhargava ◽  
Monika Kakran ◽  
Naveen Chandra Joshi ◽  
...  

Antimicrobial susceptibility testing of 258N. gonorrhoeaeisolates by Etest determined that 60.1% were MDR while 5% strains had decreased susceptibility to currently recommended extended-spectrum cephalosporins (ESCs). Among these, 84.5% MDR and 76.9% strains having decreased susceptibility to ESCs were susceptible to gentamicin. No MDR isolate was resistant to gentamicin. Thesein vitroresults suggest that gentamicin might be an effective treatment option for the MDR strains and in dual therapy for gonorrhea. However, further research regarding the clinical treatment outcomes is essential.


2017 ◽  
Vol 12 (1) ◽  
pp. S1048-S1049
Author(s):  
Pawel Krawczyk ◽  
Marcin Nicoś ◽  
Dariusz Kowalski ◽  
Rodryg Ramlau ◽  
Kinga Winiarczyk ◽  
...  

2007 ◽  
Vol 194 (2) ◽  
pp. 270 ◽  
Author(s):  
Anand Kumar Mishra ◽  
C.K. Ben Selven ◽  
Aravindan Nair ◽  
Amit Agarwal

2018 ◽  
Vol 103 (5) ◽  
pp. 540-545 ◽  
Author(s):  
Jean-Yves Reginster ◽  
Gary Hattersley ◽  
Gregory C. Williams ◽  
Ming-yi Hu ◽  
Lorraine A. Fitzpatrick ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document